Subset of Patients With Strong Response to Therapy Identified By ITN Type 1 Diabetes Study
Patients with type 1 diabetes treated with the monoclonal antibody teplizumab exhibit greater preservation of C-peptide, compared to controls, according to a new clinical trial.